Drug Profile
Research programme: cancer therapeutics - Ipsen
Alternative Names: 17 beta hydroxysteroid dehydrogenase inhibitors - Ipsen; Cytotoxic-peptide conjugates - Ipsen; DASI - Ipsen; Dual aromatase-steroid sulfatase inhibitors - Ipsen; Prolactin receptor antagonists - Ipsen; SARD - Ipsen; Selective androgen receptor degraders - Ipsen; siRNA -peptide conjugates - IpsenLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Ipsen
- Class Antineoplastics; Peptides; Small interfering RNA
- Mechanism of Action Androgen receptor degradation enhancers; Aromatase inhibitors; Estradiol dehydrogenase inhibitors; Prolactin receptor antagonists; RNA interference; Sulfatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for preclinical development in Cancer in France
- 18 Oct 2016 Preclinical development is ongoing for Cancer in France (Ipsen pipeline, October 2016)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France